Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-04

Study Completion Date

2024-06-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall goal of this collaborative research program is to develop, validate and translate advanced quantitative magnetic resonance (MR) biomarkers of obesity-associated non-alcoholic fatty liver disease (NAFLD). This protocol represents the research plan for two distinct phases. The first phase is an optimization phase. The second phase is designed to complete a rigorous test of conventional and advanced MRE techniques. Complementary anthropometric, laboratory, and MR measures will also be collected to characterize the cohort and identify factors that affect MRE performance

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non Alcoholic Fatty Liver Disease and Coronary Heart Disease in Type 2 Diabetes Patients

NCT04462081

Nonalcoholic Steatohepatitis

COMPLETED

Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00940537

Liver Diseases

COMPLETED

Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences

NCT06908122

Non-alcoholic Fatty Liver Disease

NOT_YET_RECRUITING

Liver Health and Metabolic Function in People With Obesity

NCT03701828

Non-Alcoholic Fatty Liver Disease

COMPLETED NA

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

NCT04232566

Obesity, Morbid NASH - Nonalcoholic Steatohepatitis Chronic Inflammation

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The long-term objective of this research is to improve the health of the millions of Americans with or at risk for NAFLD, the most common chronic liver disease and most rapidly growing indication for liver transplantation in the United States. To achieve this objective, an advanced MR-based imaging method will be used to measure liver "stiffness" which is an early sign of disease. This technique has been previously developed and validated and ready to be used for further research. This current protocol will extend previous work by optimizing and validating advanced 2 dimensional and 3 dimensional-magnetic resonance elastography (MRE) methods as non-invasive biomarkers of hepatic inflammation and fibrosis in obese patients at risk for non-alcoholic steatohepatitis (NASH), the histologically more aggressive subset of NAFLD.

Per Amendment approved 4/8/22: MRE exams will be conducted using a PDFF Pocket Phantom purchased by the UCSD from Calimetrix. This phantom consists of vials with known fat fraction which are captured when taking images of the liver. The known fat fractions provide an independent reference and are used for quality assurance purposes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease Non-alcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Subjects with a BMI of 35 or more will be asked to undergo a single MRE imaging session.

Magnetic Resonance Elastography (MRE)

Intervention Type OTHER

The MRE scan will several breath holds and will take approximately 30 minutes to complete.

Patient Group

Adults that are candidates for weight loss surgery will be asked to participate in four study visits that include MRE imaging and 1 - 2 liver biopsy procedures.

Magnetic Resonance Elastography (MRE)

Intervention Type OTHER

The MRE scan will several breath holds and will take approximately 30 minutes to complete.

Liver biopsy

Intervention Type DIAGNOSTIC_TEST

Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Elastography (MRE)

The MRE scan will several breath holds and will take approximately 30 minutes to complete.

Intervention Type OTHER

Liver biopsy

Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MRI Intraoperative Biopsy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of at least 18 years
* Severely obese (BMI ≥ 35 kg/m2) patient

* Cleared for weight-loss surgery
* Willing and able to complete all safety and follow-up procedures
* Willing to allow for the banking of biological samples

Exclusion Criteria

* Contraindications to MRI
* Girth or weight that exceeds scanner capacity
* Women of childbearing potential that are pregnant or will be attempting to become pregnant during the study duration.

* Known liver malignancies
* Regular \& excessive alcohol consumption within 2 years prior to recruitment
* Use of steatogenic or hepatotoxic drugs
* Clinical or laboratory evidence of liver disease other than Nonalcoholic fatty liver disease (NAFLD)/ Nonalcoholic steatohepatitis (NASH) (e.g. HCV Ab, HBV Ab, ceruloplasmin)
* The subject has increased bleeding risk (i.e., decreased platelets, von Willebrand disease)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes